Clinical Trial Update: A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety, tolerability, and efficacy of AP1189 in early rheumatoid arthritis with active joint disease; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• AP1189

Snippet

Sponsor: SynAct Pharma Aps | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2024-07-10